Made Scientific Expands Board to Support Growth Strategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Source: Newsfilter
- Board Expansion: Made Scientific announces the appointment of Ted Dolan and Soyoung Park to its Board, aiming to enhance governance structures that support the company's transition towards late-phase cell therapy manufacturing, thereby improving operational capabilities in complex environments.
- Manufacturing Capacity Increase: The company is expanding its GMP manufacturing capacity at its Princeton, NJ campus to meet the growing demand from advanced therapy developers, ensuring reliable execution and scalability as programs approach commercialization.
- Strategic Investment Support: Made Scientific is backed by long-term strategic shareholder GC Corporation, reflecting a shared commitment to prioritizing scale and quality over short-term outcomes, thus laying a foundation for the future of cell therapy manufacturing.
- Leadership Team Background: New board members Ted Dolan and Soyoung Park bring extensive experience in the CDMO and biopharmaceutical sectors, providing deep expertise that enhances the company's execution capabilities in complex projects, further strengthening its competitive position in the market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
